Publications by authors named "Marjolein Koetsier"
Direct Comparison of Real-world Effectiveness of Biologics for Psoriasis using Absolute and Relative Psoriasis Area and Severity Index Scores in a Prospective Multicentre Cohort.
Acta Derm Venereol
May 2022
Article Synopsis
- A study was conducted to compare the effectiveness of different biologic therapies for psoriasis, including IL17-inhibitors and TNF-α-inhibitors, using real-world data.
- Researchers analyzed data from 1,080 treatment episodes involving 700 psoriasis patients to assess outcomes like the mean Psoriasis Area and Severity Index (PASI) and how many patients achieved PASI90 or PASI75.
- Results showed that patients on adalimumab, ustekinumab, secukinumab, ixekizumab, and guselkumab had better outcomes than those on etanercept, with ixekizumab and guselkumab leading to even higher rates of achieving PASI90 compared to the other biologics
Background: is a nontuberculous mycobacterium that causes skin and soft tissue infections. Treatment consists of multiple antibiotics, sometimes combined with surgical debridement. There is little evidence for the choice of antibiotics, the duration of treatment, and the role of susceptibility testing.
View Article and Find Full Text PDFSerum drug levels and anti-drug antibodies in the context of dose tapering by interval prolongation of adalimumab, etanercept and ustekinumab in psoriasis patients: results of the CONDOR trial.
J Dermatolog Treat
August 2022
Article Synopsis
- Biologics for psoriasis can be safely reduced in dosage for patients with low disease activity to avoid overtreatment and reduce costs, though concerns about increased anti-drug antibody (ADA) formation exist.
- * The study involved 118 patients who were randomly assigned to either dose reduction (DR) or usual care (UC) over one year, examining serum drug concentrations and ADA levels.
- *Results showed no significant difference in ADA levels for adalimumab between DR and UC, and no relevant ADA development for ustekinumab; this suggests that dose tapering may not increase immunogenicity in low disease activity psoriasis patients.
Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study.
Acta Derm Venereol
December 2020
A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The aim of the current study was to perform a cost-utility analysis with a 12-month time horizon alongside this trial, using prospectively measured healthcare costs and quality-adjusted life years, based on Short-Form Six-Dimension utilities. Bootstrap analys-es were used to calculate the decremental cost-utility ratio and the incremental net monetary benefit.
View Article and Find Full Text PDFImportance: Biologics revolutionized the treatment of psoriasis. Biologics are given in a fixed dose, but lower doses might be possible.
Objective: To investigate whether dose reduction (DR) of biologics in patients with stable psoriasis is noninferior to usual care (UC).
UDP-glucuronosyltransferase 1A6 (UGT1A6) is involved in metabolizing non-steroidal anti-inflammatory drugs (NSAIDs). Genotype variation in UGT1A6 may influence the metabolism of NSAIDs and we studied whether this might modulate the gastrointestinal toxicity of NSAIDs. UGT1A6 genotypes of 114 patients with peptic ulcer haemorrhage were compared with those of two subsets of controls: 158 cardiology patients using similar amounts of NSAIDs and 140 healthy controls, hardly using NSAIDs.
View Article and Find Full Text PDFCyclooxygenases (COX) catalyze the conversion of arachidonic acid to prostaglandins (PGs). COX-inhibiting drugs, such as nonsteroidal anti-inflammatory drugs (NSAIDs), increase the risk for peptic ulcer disease. As a corollary, COX gene polymorphisms could be important in the pathogenesis of peptic ulcer disease because these affect prostaglandin formation and impair its protective effect at the level of the gastric mucosa.
View Article and Find Full Text PDF